@article{Morton_B-2021_41535,
title = {Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa},
author = {Morton, B. and Barnes, K. and Anscombe, C. and Jere, K. and Matambo, P. and Mandolo, J. and Kamng’ona, R. and Brown, C. and Nyirenda, J. and Phiri, T. and Banda, N. and Van Der Veer, C. and Mndolo, K. and Mponda, K. and Rylance, J. and Phiri, C. and Mallewa, J. and Nyirenda, M. and Katha, G. and Kambiya, P. and Jafali, J. and Mwandumba, H. and Gordon, S. and Cornick, J. and Jambo, K. and Blantyre COVID-19 Consortium},
month = {jun},
year = {2021},
abstract = {Abstract: Although the COVID-19 pandemic has left no country untouched there has been limited research to understand clinical and immunological responses in African populations. Here we characterise patients hospitalised with suspected (PCR-negative/IgG-positive) or confirmed (PCR-positive) COVID-19, and healthy community controls (PCR-negative/IgG-negative). PCR-positive COVID-19 participants were more likely to receive dexamethasone and a beta-lactam antibiotic, and survive to hospital discharge than PCR-negative/IgG-positive and PCR-negative/IgG-negative participants. PCR-negative/IgG-positive participants exhibited a nasal and systemic cytokine signature analogous to PCR-positive COVID-19 participants, predominated by chemokines and neutrophils and distinct from PCR-negative/IgG-negative participants. PCR-negative/IgG-positive participants had increased propensity for Staphylococcus aureus and Streptococcus pneumoniae colonisation. PCR-negative/IgG-positive individuals with high COVID-19 clinical suspicion had inflammatory profiles analogous to PCR-confirmed disease and potentially represent a target population for COVID-19 treatment strategies.},
volume = {12},
journal = {Nature Communications},
publisher = {Springer Nature},
url = {https://doi.org/10.1038/s41467-021-23267-w},
}
